- Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Candel Therapeutics to Join Russell 3000® Index
- FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
- Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
- Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
- Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
- Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
- Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
More ▼
Key statistics
On Wednesday, Candel Therapeutics Inc (CADL:NMQ) closed at 6.31, 856.06% above the 52 week low of 0.66 set on Nov 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.27 |
---|---|
High | 6.34 |
Low | 6.01 |
Bid | 6.13 |
Offer | 6.31 |
Previous close | 6.25 |
Average volume | 872.90k |
---|---|
Shares outstanding | 29.76m |
Free float | 19.72m |
P/E (TTM) | -- |
Market cap | 185.98m USD |
EPS (TTM) | -1.29 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼